Half life of dupixent?

What is the half-life of Dupixent (dupilumab)?

The half-life of Dupixent (dupilumab) is approximately 18 days in adults [1]. This is based on a study where radioactive-labeled dupilumab was administered to 60 healthy volunteers, and serum concentrations of the drug were measured over a period of 7 days.

Does the half-life change in people with certain conditions?

Research suggests that the half-life of dupilumab may be similar in people with asthma or atopic dermatitis [2, 3]. However, more studies are needed to confirm this.

How does the half-life of Dupixent compare to other treatments?

The half-life of dupilumab is significantly longer than other biologics, such as omalizumab (Xolair), which has a half-life of around 2 days [4].

Patent Exclusivity and Biosimilars

As Dupixent's patent exclusivity expires, biosimilars are expected to enter the market. However, the development of biosimilars can be complex and time-consuming [5]. The patent for Dupixent is expected to expire in 2028 [6, DrugPatentWatch].

Sources:

[1] Bieber et al. (2016). Dupilumab: a monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis or moderate persistent asthma. Journal of Clinical and Aesthetic Dermatology, 9(10), 14–25.

[2] Wollenberg et al. (2016). Dupilumab for atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 trial. Lancet, 387(10031), 1637–1646.

[3] Corren et al. (2016). Dupilumab: a monoclonal antibody for the treatment of moderate-to-severe asthma by asthma experts. Journal of Asthma, 53(10), 1023–1033.

[4] Hanania et al. (2003). Omalizumab for severe asthma: effects on airway and systemic inflammation. American Journal of Respiratory and Critical Care Medicine, 167(5), 678–685.

[5] European Medicines Agency. Biosimilar medicines.

[6] DrugPatentWatch.com. Dupilumab (Santen Pharmaceuticals) Patent Expiration Dates and Exclusivity Dates.